Mitochondria Emerge as the Central Hub Driving Diabetic Nerve Damage

Diabetic neuropathy, one of the most common and debilitating complications of diabetes, has long been blamed on chronically high blood sugar. But a comprehensive new review published in the Journal of Translational Medicine argues that the story is far more intricate. A team led by Xiaotong Wu and Shihong Chen of the Second Qilu Hospital of Shandong University synthesizes evidence that damaged mitochondria—the tiny power plants inside our cells—act as a central pathogenic hub connecting metabolic overload, inflammation, and progressive nerve degeneration. The review, published open access on 17 October 2026, draws together mechanistic, translational, observational, and interventional studies to argue that treating diabetic neuropathy effectively will require targeting mitochondrial biology directly, not merely masking symptoms.

The clinical problem is enormous. Diabetic neuropathy encompasses a heterogeneous set of conditions: loss of sensation in the feet, burning neuropathic pain, dysfunction of the autonomic nerves that regulate the heart and gut, and the slow degeneration of the long axons that connect the spinal cord to the toes. High blood glucose alone cannot fully explain this spectrum. What unites these presentations, the authors contend, is the extraordinary bioenergetic demand of peripheral nerves. Long axons, the Schwann cells that insulate them, and autonomic neurons all depend on a continuous supply of ATP generated by oxidative phosphorylation. When mitochondria falter, these cells are among the first to suffer, which is precisely why the longest nerve fibers—those serving the feet—degenerate first.

At the biochemical level, the review describes how hyperglycaemia, lipotoxicity, and microvascular stress conspire to impair the electron transport chain, the series of protein complexes that shuttles electrons to generate the proton gradient driving ATP synthesis. When electron transport becomes inefficient, electrons leak and combine with oxygen to form reactive oxygen species at rates that overwhelm cellular antioxidant defenses. The resulting oxidative attack damages mitochondrial DNA, producing markers such as 8-hydroxy-2′-deoxyguanosine, and oxidizes membrane lipids, generating aldehydes like 4-hydroxynonenal and malondialdehyde. Calcium handling deteriorates in parallel: excess cytosolic calcium floods the mitochondrial matrix through the mitochondrial calcium uniporter, and sustained stress triggers opening of the mitochondrial permeability transition pore, a catastrophic event that collapses the proton gradient and can commit the cell to death.

Beyond energy failure, the review emphasizes that mitochondria in neurons are dynamic organelles that must be continuously maintained, moved, and recycled. In healthy axons, a balance between fission and fusion—orchestrated by proteins such as dynamin-related protein 1, mitofusins, and optic atrophy 1—keeps the mitochondrial network functional. Diabetes disrupts this balance, tilting it toward excessive fragmentation. At the same time, the molecular motors that transport fresh mitochondria along microtubules to distal axon terminals falter, starving the nerve periphery of ATP exactly where it is needed most. Mitophagy, the quality-control process that identifies and digests damaged mitochondria via the PINK1–Parkin pathway and receptors such as optineurin and nuclear dot protein 52, becomes defective, allowing dysfunctional organelles to accumulate. Contacts between mitochondria and the endoplasmic reticulum, formed at mitochondria-associated ER membranes, also become abnormal, disturbing calcium transfer and lipid exchange between the two organelles.

One of the most striking sections of the review connects mitochondrial collapse to a newly recognized executioner of axons: the protein SARM1. When levels of the metabolic cofactor NAD+ fall—a direct consequence of mitochondrial dysfunction—SARM1 switches on and degrades remaining NAD+, triggering a self-destructive program that dismantles the axon from within. This places bioenergetic failure and axonal degeneration on a single mechanistic continuum. The authors also describe how damaged mitochondria release danger signals that activate the NLRP3 inflammasome, driving maturation of the inflammatory cytokines interleukin-1 beta and interleukin-18, and how mitochondrial DNA escaping into the cytoplasm engages the cGAS–STING pathway, provoking type I interferon responses. Together, these pathways convert intracellular energy failure into neuroinflammation, glial dysfunction, pain sensitization, and ultimately cell death.

A key insight of the review is that mitochondrial mechanisms appear to be shared across the different faces of diabetic neuropathy, even though the dominant cell types and clinical endpoints differ. In painful diabetic peripheral neuropathy, mitochondrial stress in sensory neurons and satellite glial cells of the dorsal root ganglion contributes to the hypersensitivity that characterizes chronic pain. In painless disease, the same bioenergetic collapse drives silent distal axonal loss and insensate feet at risk of ulceration. Corneal small-fibre neuropathy, increasingly assessed non-invasively with corneal confocal microscopy, reflects similar small-fibre mitochondrial injury, while cardiovascular autonomic neuropathy involves mitochondrial failure in autonomic neurons. Even diabetes-related injury in the central nervous system shows overlapping mitochondrial signatures, suggesting a unifying framework for what has historically been treated as a collection of separate syndromes.

The translational implications are where the review becomes most provocative. The authors survey a wide range of metabolism-oriented interventions currently under investigation. Exercise and dietary strategies can improve mitochondrial biogenesis through the AMPK–PGC-1 alpha axis and enhance insulin sensitivity. Metabolic regulators aim to redirect excess substrate away from overloaded electron transport chains. SARM1 inhibitors represent an emerging class designed to block the axon-destruction pathway directly, while calcium-pathway targeting seeks to prevent permeability transition pore opening and excitotoxic calcium overload. Mitophagy modulation aims to restore quality control, and mitochondria-directed antioxidants such as MitoQ and MitoTEMPO are engineered to accumulate inside mitochondria, where generic antioxidants like alpha-lipoic acid penetrate poorly. The authors also discuss traditional Chinese medicine and natural products, which contain compounds with mitochondrial-protective activities, though they stress that these require rigorous mechanistic and clinical validation.

Despite this wealth of mechanisms, the review is notably sober about the state of clinical evidence. The authors conclude that while target engagement has been demonstrated in experimental systems—cells, animal models, and early human biomarker studies—human validation remains insufficient. Tissue exposure data for many candidate drugs are lacking, structural nerve endpoints such as intraepidermal nerve fibre density and corneal nerve measures are inconsistently incorporated into trials, and high-quality disease-modifying trials are scarce. The narrative review format also carries limitations: the authors explicitly note that no formal risk-of-bias tool or GRADE assessment was applied, instead distinguishing human, animal, and cellular evidence narratively. The search drew on PubMed from database inception to 1 August 2026, supplemented by backward reference screening, prioritizing English-language mechanistic and translational studies.

Perhaps the most important message for patients and clinicians is a reframing of what treatment should aim for. Current management of diabetic neuropathy is largely symptomatic—pain relievers for discomfort and glycaemic control to slow progression—but does not repair damaged nerves. The review argues that the most actionable translational path is not symptomatic antioxidant use alone, which has repeatedly produced disappointing trial results, but biomarker-guided, mechanism-stratified trials. In practice, this would mean measuring mitochondrial targets in accessible tissues, stratifying patients by the dominant mechanism driving their disease, and connecting mitochondrial target modulation with small-fibre structure, nerve function, safety, and patient-centred outcomes such as pain, balance, and quality of life.

Mitochondrial dysfunction, the authors conclude, functions as a core pathogenic hub rather than the sole cause of diabetic neuropathy—a convergence point where substrate overload, redox imbalance, calcium stress, organelle quality-control failure, inflammatory signalling, and axonal degeneration meet. As diabetes rates continue to climb worldwide, and with no approved disease-modifying therapy for diabetic neuropathy, the review’s framework offers researchers a map of where to intervene next. Whether SARM1 inhibitors, mitophagy enhancers, or targeted mitochondrial antioxidants can finally change the trajectory of this devastating complication will depend on the rigorous, biomarker-driven human trials the authors say are urgently needed.

Subject of Research: Mitochondrial dysfunction as a pathogenic hub in diabetic neuropathy and its therapeutic implications

Article Title: Mitochondrial dysfunction in diabetic neuropathy: a core pathogenic hub and therapeutic implications

Article References: Wu, X., Li, X., Lou, N., Zhuang, X., & Chen, S. (2026). Mitochondrial dysfunction in diabetic neuropathy: a core pathogenic hub and therapeutic implications. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09015-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09015-y

Keywords: diabetic neuropathy, mitochondrial dysfunction, oxidative stress, mitophagy, SARM1, neuroinflammation, NLRP3 inflammasome, cGAS-STING, axonal degeneration, diabetic peripheral neuropathy, mitochondria-targeted antioxidants, Journal of Translational Medicine